Headquartered in Jersey City, NJ Fiscal year ends December NYSE: OGN organon.com
Organon & Co. (NYSE: OGN) is a global healthcare company with a portfolio of over 70 products spanning Women's Health and General Medicines, which includes biosimilars and established brands. The Women's Health franchise features key products such as Nexplanon (contraceptive implant), NuvaRing, fertility treatments (Follistim AQ, Ganirelix Acetate), and Marvelon/Mercilon oral contraceptives. The General Medicines franchise encompasses a growing biosimilars portfolio including Hadlima, Renflexis, Ontruzant, Brenzys, Tofidence, and Bildyos/Bilprevda, as well as established brands across cardiovascular (Zetia, Cozaar/Hyzaar, Atozet), respiratory (Singulair, Nasonex, Dulera), non-opioid pain and dermatology (Arcoxia, Vtama, Fosamax, Diprospan), and other therapeutic areas (Emgality for migraine, Propecia, Proscar). The company operates in over 140 markets worldwide and recently acquired Dermavant Sciences to add the dermatology product Vtama to its portfolio. Organon divested its JADA postpartum hemorrhage system in January 2026. The company carries approximately $8.6 billion in debt and is focused on deleveraging while maintaining operational performance. Updated
Pre-Market Stock Futures: Futures are trading mostly lower after a rather ho-hum start to the trading week on Monday. While the S&P 500 and the Nasdaq did print new highs before fading…
The Nasdaq Composite (^IXIC) is trading in the green at Friday’s open, with the index leading the major averages as legacy chipmaker Intel’s blowout earnings report reignites the AI-infrastructure trade. The Nasdaq…
Organon & Co. (NYSE: OGN) is a global healthcare company with a portfolio of over 70 products spanning Women's Health and General Medicines, which includes biosimilars and established brands.
24/7 Wall St.'s 12-month price target for OGN is $15.02, rated Buy. The Wall Street consensus target is $11.25. OGN price prediction →
